Last reviewed · How we verify
NCT03855774: SOCAF
Polymorphisms, Caffeine and Sleep Disorders
NA trial testing Polymorphisms in Polymorphism in 1,100 participants. Completed in 1 December 2018.
1 January 2018
Quick facts
| Lead sponsor | Institut de Recherche Biomedicale des Armees |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 1,100 |
| Start date | 1 January 2018 |
| Primary completion | 1 January 2018 |
| Estimated completion | 1 December 2018 |
| Sites | 1 location across France |
Drugs / interventions tested
- Polymorphisms
Conditions studied
- Polymorphism — all drugs for Polymorphism →
- Sleep Disorder — all drugs for Sleep Disorder →
- Coffee-Workers' Disease — all drugs for Coffee-Workers' Disease →
Sponsor
Institut de Recherche Biomedicale des Armees
Who can join
Adults 18 to 60, any sex, with Polymorphism or Sleep Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Screening of a population of volunteer workers recruited on the occasion of their occupational health visit, within the Ministry of Defense and civil enterprises. The voluntary subjects included will, after signing a consent, take a saliva sample (Kit Oragen DNA OG500) and fill out a computerized questionnaire. A posteriori, the genotyping polymorphisms may be associated with variations in the pharmacokinetics or pharmacodynamics of caffeine will be achieved. The primary objective is to determine whether polymorphisms (alone or in combination) of genes associated with the pharmacokinetics or pharmacodynamics of caffeine are independent risk factors for sleep disorders. The secondary objectives are to determine the frequency of these polymorphisms and to evaluate the consequences of these associations on sleep habits (sleep time, chronotype, quality of sleep), daytime sleepiness, caffeine consumption, antecedents of accidents at work or traffic, drug consumption ...
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Impact of Genetic Variations in ADORA2A in the Association between Caffeine Consumption and Sleep.
Erblang M, Drogou C, Gomez-Merino D, Metlaine A, et al · · 2019 · cited 33× · PMID 31817803 · DOI 10.3390/genes10121021
Verify or expand the search:
- PubMed search for NCT03855774
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Institut de Recherche Biomedicale des Armees trials
Trials by the same sponsor.
- NCT05924737 — Delta Waves and Cognitive Recovery · NA · completed
- NCT05924659 — Neurofeedback Training's Efficiency for Attentionnal Performances · NA · recruiting
- NCT03995992 — Benefits of Diving Training on Recovery for Veterans Suffering of Chronic PTSD: an Exploratory Study · NA · unknown
- NCT03990064 — Benefits of Relaxation by Music Therapy on PTSD Symptoms · NA · terminated
- NCT03859882 — Protocol PERCAF 2018 · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03855774 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut de Recherche Biomedicale des Armees
- Last refreshed: 28 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03855774.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing